Tc 99m tilmanocept

Drug Profile

Tc 99m tilmanocept

Alternative Names: Lymphoseek; NEO3-09; Tc 99m-diethylenetriamine pentaacetic acid mannosyl dextran; Tc 99m-DTPA-mannosyl dextran; Technetium Tc 99m tilmanocept; Tilmanocept

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator University of California, San Diego
  • Developer Maimonides Medical Center; Navidea Biopharmaceuticals; University of California, San Diego
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Breast cancer; Head and neck cancer; Malignant melanoma
  • Registered Solid tumours; Squamous cell cancer
  • Phase II Cervical cancer; Kaposi's sarcoma
  • Phase I Cardiovascular disorders; Endometrial cancer; Rheumatoid arthritis
  • Clinical Phase Unknown Colorectal cancer

Most Recent Events

  • 20 Jan 2017 Navidea Biopharmaceuticals, National Institutes of Health and National Cancer Institute plan a phase I trial for Liver metastases (Diagnosis) in USA (IV and SC) (NCT03029988)
  • 01 Jan 2017 Phase-I clinical trials in Rheumatoid arthritis (Diagnosis) in USA (IV)
  • 01 Dec 2016 Navidea Biopharmaceuticals completes a phase I trial in Rheumatoid arthritis (Diagnosis) in USA (Intradermal) (NCT02683421)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top